Concentrix (NASDAQ:CNXC – Get Free Report) updated its second quarter 2024 earnings guidance on Tuesday. The company provided EPS guidance of 2.550-2.700 for the period, compared to the consensus EPS estimate of 2.830. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.4 billion. Concentrix also updated its FY 2024 guidance to 11.690-12.500 EPS.
Concentrix Stock Up 4.8 %
Concentrix stock opened at $65.20 on Thursday. Concentrix has a one year low of $59.23 and a one year high of $125.80. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.38 and a current ratio of 1.38. The stock has a fifty day moving average of $78.34 and a 200 day moving average of $83.61. The stock has a market cap of $4.32 billion, a PE ratio of 11.30, a price-to-earnings-growth ratio of 0.66 and a beta of 0.50.
Concentrix (NASDAQ:CNXC – Get Free Report) last posted its quarterly earnings results on Wednesday, January 24th. The company reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.92 by $0.15. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.20 billion. Concentrix had a net margin of 3.53% and a return on equity of 18.77%. As a group, sell-side analysts predict that Concentrix will post 11.26 EPS for the current year.
Concentrix Increases Dividend
Wall Street Analyst Weigh In
CNXC has been the subject of several recent analyst reports. Barrington Research decreased their price target on Concentrix from $121.00 to $84.00 and set an outperform rating for the company in a research note on Wednesday. Bank of America reissued an underperform rating and set a $60.00 target price (down from $85.00) on shares of Concentrix in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $95.80.
Check Out Our Latest Analysis on Concentrix
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. Cambridge Investment Research Advisors Inc. raised its position in Concentrix by 7.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,859 shares of the company’s stock valued at $310,000 after purchasing an additional 133 shares during the period. BlackRock Inc. boosted its stake in shares of Concentrix by 1.0% during the 1st quarter. BlackRock Inc. now owns 3,668,975 shares of the company’s stock worth $611,103,000 after purchasing an additional 35,619 shares during the last quarter. Great West Life Assurance Co. Can grew its position in shares of Concentrix by 8.0% during the first quarter. Great West Life Assurance Co. Can now owns 23,644 shares of the company’s stock worth $4,049,000 after buying an additional 1,761 shares in the last quarter. Sei Investments Co. raised its position in Concentrix by 168.7% in the first quarter. Sei Investments Co. now owns 22,904 shares of the company’s stock worth $3,823,000 after acquiring an additional 14,380 shares in the last quarter. Finally, Aviva PLC acquired a new stake in shares of Concentrix in the first quarter worth $593,000. Hedge funds and other institutional investors own 90.34% of the company’s stock.
Concentrix Company Profile
Concentrix Corporation engages in the provision of technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services, across various channels of communication, such as voice, chat, email, social media, asynchronous messaging, and custom applications.
Read More
- Five stocks we like better than Concentrix
- High Flyers: 3 Natural Gas Stocks for March 2022
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Ride Out The Recession With These Dividend KingsĀ
- 7 Stocks That Will Drive the Weight Loss Drugs Market
- What Are Dividend Champions? How to Invest in the Champions
- Cintas or UniFirst: Investors Win Either Way
Receive News & Ratings for Concentrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concentrix and related companies with MarketBeat.com's FREE daily email newsletter.